Prevention of atrial fibrillation complications with antiarrhythmic drugs: Still an unmet need in clinical practice

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1195-1199

  Dobrev, Dobromir ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

antiarrhythmic drugs; atrial fibrillation; mechanisms; oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DEETHYLAMIODARONE; DOFETILIDE; DRONEDARONE; EDOXABAN; FLECAINIDE; IBUTILIDE; PADGEM PROTEIN; PROPAFENONE; RIVAROXABAN; VON WILLEBRAND FACTOR; WARFARIN;

BLEEDING; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIVER DISEASE; LIVER TOXICITY; REVIEW; SINUS RHYTHM; STROKE; TREATMENT RESPONSE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; HEART RATE; HUMANS; STROKE;

EID: 79955830988     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.568476     Document Type: Review

References (25)

1. Dobrev D, Nattel S.New antiarrhythmic drugs for treatment of atrial fibrillation.Lancet 2010;375:1212-23
2. Wyse DG, Waldo AL, DiMarco JP, et al.A comparison of rate control and rhythm control in patients with atrial fibrillation.N Engl J Med 2002;347:1825-33 (Pubitemid 35417773)
3. Van Gelder IC, Hagens VE, Bosker HA, et al.A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.N Engl J Med 2002;347:1834-40 (Pubitemid 35417774)
4. Marinelli A, Capucci A.Antiarrhythmic drugs for atrial fibrillation.Expert Opin Pharmacother 2011;12(8):1201-1215
5. Nattel S, Burstein B, Dobrev D.Atrial remodeling and atrial fibrillation: mechanisms and implications.Circ Arrhythm Electrophysiol 2008;1:62-73
6. Dobrev D, Nattel S.Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics.J Cardiovasc Pharmacol 2008;52:293-9
7. Sood S, Chelu MG, van Oort RJ, et al.Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation.Heart Rhythm 2008;5:1047-54
8. Michael G, Xiao L, Qi XY, et al.Remodeling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis.Cardiovasc Res 2009;81:491-9
9. Chelu MG, Sarma S, Sood S, et al.Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice.J Clin Invest 2009;119:1940-51
10. Dobrev D.Electrical remodeling in atrial fibrillation.Herz 2006;31:108-12 (Pubitemid 43899995)
11. Dobrev D, Voigt N, Wehrens XH.The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications.Cardiovasc Res 2010;89(4):734-43
12. Hohnloser SH, Crijns HJ, van Eickels M, et al.Effect of dronedarone on cardiovascular events in atrial fibrillation.N Engl J Med 2009;360:668-78
13. Hammwohner M, Goette A.Will warfarin soon be passe? New approaches to stroke prevention in atrial fibrillation.J Cardiovasc Pharmacol 2008;52:18-27
14. Lamassa M, Di Carlo A, Pracucci G, et al.Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).Stroke 2001;32:392-8 (Pubitemid 32155224)
15. Aguilar MI, Hart R, Pearce LA.Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.Cochrane Database Syst Rev 2007;3:CD006186
16. Ezekowitz MD, James KE, Nazarian SM, et al.Silent cerebral infarction in patients with nonrheumatic atrial fibrillation.The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.Circulation 1995;92(8):2178-82
17. Knecht S, Oelschlager C, Duning T, et al.Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy.Eur Heart J 2008;29:2125-32
18. van Walraven C, Hart RG, Singer DE, et al.Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.JAMA 2002;288:2441-8 (Pubitemid 35340540)
19. Connolly S, Pogue J, Hart R, et al.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial.Lancet 2006;367:1903-12
20. Lip GY, Edwards SJ.Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.Thromb Res 2006;118:321-33 (Pubitemid 44067199)
21. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E.The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest 2004;126(3 Suppl):204S-33S (Pubitemid 39297955)
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med 2009;361:1139-51
23. Nagarakanti R, Ezekowitz MD, Oldgren J, et al.Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.Circulation 2011;123:131-6
24. Lip GY, Frison L, Halperin JL, Lane DA.Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation The HAS-BLED (hypertension,abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score.J Am Coll Cardiol 2011;57:173-80
25. Themistoclakis S, Corrado A, Marchlinski FE, et al.The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.J Am Coll Cardiol 2010;55:735-43